Clinical Trials

We have initiated a Phase 3 clinical study of MST-188 (purified poloxamer 188) for the treatment of sickle cell disease. For more information, please visit theEPICstudy.com or the study detail page at ClinicalTrials.gov.*

*Links to third-party Internet sites are provided on this site for your convenience. Such sites are not under our control. Linking to third-party Internet sites does not indicate or imply any endorsement of or sponsorship by us of such sites or the information, products or services offered on or through such sites. We expressly disclaim any responsibility for the privacy policies and information collection practices of such third-party sites, as well as the content, accuracy of information and/or quality of such sites, including any products and/or services provided by or advertised on such sites. You are responsible for complying with all terms and conditions governing the use of such third-party Internet sites.

News

Click here to view our latest press releases, SEC filings, and information about company events, media, and analyst coverage. read more

Patient Resources

Click here to view our Patient Resources page, with information such as community organizations and news read more

Technology

Click here to learn more about our lead product candidate, MST-188, as well as our other technologies. read more